Does this mean it's time to dump your Moderna shares? First, it's important to note that Moderna's difficult times may not be over.

Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as it works to develop its product portfolio while cutting costs.

Moderna MRNA 0.69% was once a darling of the first Trump administration, which went to great lengths to help the company develop its Covid-19 vaccine that protected millions of people from the virus.

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.

The FDA has approved Moderna's new COVID-19 shot, an mRNA vaccine called mNexspike, with some limits on who can get it.

The new COVID-19 vaccine from Moderna, mNexspike, is made in a way that allows for a lower dose.

The Department of Health and Human Services (HHS) is canceling hundreds of millions of dollars in funding pledged to Moderna to help the company develop, test and license mRNA-based vaccines to com… ...

The Department of Health and Human Services (HHS) has axed a $590 million contract with Moderna, raising doubts about how the biotech will fund late-phase development of a pandemic bird flu vaccine.

Moderna had been developing a vaccine to combat an outbreak of bird flu in dairy cattle in spring 2024, but the U.S. government is rescinding millions of dollars in funding.

HHS has notified Moderna that it is canceling a nearly $600 million contract for vaccines for flu strains that could trigger future pandemics.

Shares of Moderna surged to lead S&P 500 gainers Tuesday after the Food and Drug Administration issued new guidance for COVID-19 vaccine boosters.

Why Vaccine-Maker Moderna Is Injecting AI Across the Company More than 3,000 GPTs are reportedly in use at Moderna, which has partnered with OpenAI.